Nine studies compared serum or plasma NfL levels in ATTRv amyloidosis patients with polyneuropathy to concentrations in neurologically asymptomatic TTRv carriers, asymptomatic ATTRv patients, or healthy controls [23,24,25,33,34,35,39,40,41]. This evidence concerns the gene NEFL and amyloidosis.